CONTACT

TerminatedPhase 3

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease

Lead sponsor

Medivation, Inc.

Asset

Dimebon

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•MMSE 5-14

Primary endpoints

•Neuropsychiatric Inventory (NPI)•ADCS-Activities of Daily Living (ADCS-ADL)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDDIM19

NCT IDNCT00954590

Timeline

Milestones

Study first posted2009-08-07estimated

Study start2009-10 (month precision)

Primary completion2010-08actual (month precision)

Last update posted2016-09-27estimated

Assets

Drug assets

Dimebon

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Moderate-to-Severe Alzheimer's disease

•Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive

•Stable on donepezil for at least 6 months

Exclusion criteria

•Other causes of dementia

•Major structural brain disease

•Unstable medical condition or significant hepatic or renal disease

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Function / daily living

Behavior / neuropsychiatric

Function / daily living

1 endpoint

Primary/protocol endpoint

Activities of Daily Living (severe) (ADCS ADLsev)

Time frame:26 weeks post baseline

ADCS-Activities of Daily Living (ADCS-ADL)

descriptive

Behavior / neuropsychiatric

1 endpoint

Primary/protocol endpoint

Neuropsychiatric Inventory (NPI)

Time frame:26 weeks post baseline

Neuropsychiatric Inventory (NPI)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.